Mount Sinai and RenalytixAI launch artificial intelligence solution for improved kidney disease management and patient care
Mount Sinai Health System (MSHS) and RenalytixAI have entered into an exclusive multi-year license and collaboration to commercialize artificial intelligence solutions to improve kidney disease detection, management and treatment for patients with diabetes and other at-risk, large-scale patient populations.
The partnership will leverage MSHS’s massive data warehouse containing over 3,000,000 patient health records and 43,000 patient records in the BioMeTM BioBank repository, and using de-identified clinical data, will create an advanced learning system to monitor and flag patients at risk for kidney disease and costly unplanned “crashes” into dialysis. The first product launch is anticipated in Q2 2019 targeting the heart of the $98 billion in preventable dialysis and chronic kidney disease costs. Additional major U.S. based healthcare systems are expected to participate in clinical utility data development and product launch.
This is a significant partnership for RenalytixAI with one of the largest hospital groups in the United States. The technology alongside the Mount Sinai patient database will improve patient care in End Stage Renal Disease, a significant unmet medical need. The fact that so many patients on dialysis have never seen a specialist has to change both from a patient care and cost perspective.
Approximately 1 million patients cared for in the MSHS are either diagnosed with Type II diabetes or are of African ancestry, two of the major at-risk population segments for kidney disease. The MSHS is one of the largest integrated healthcare systems in the U.S. with over 6,500 physicians and 6,300 faculty.
RenalytixAI expects to pursue expanded clinical utility trials through collaborations with leading academic medical centers, pharmaceutical, and patient advocacy organizations in the United States and Europe beginning in 2018, followed by submission of product applications for review by the U.S. Food and Drug Administration.